HuidaGene Therapeutics Gains FDA Clearance for First CRISPR/Cas13 RNA-Editing Therapy HG202 to Treat Macular Degeneration

Complete Genomics Unveils New Sequencing Innovations and Expanded DNBSEQ-T7 Applications at ASHG 2024

QIAGEN’s QIAstat-Dx Meningitis/Encephalitis Panel Gains FDA Clearance, Accelerating CNS Infection Diagnosis

Tempus AI to Acquire Ambry Genetics for $600 Million, Expanding Genetic Testing Capabilities

Aiforia and Paige form strategic partnership to advance AI integration in pathology laboratories

CytoDyn Receives FDA Clearance to Begin Phase II Trial of Leronlimab for Colorectal Cancer

MGM Medical College in Indore Pioneers CAR T Cell Therapy for Blood Cancer Treatment in India’s Public Healthcare System

AbbVie and EvolveImmune Therapeutics Partner in New Collaboration and Licensing Agreement to Advance Next-Generation Cancer Biotherapeutics

Cardiff Oncology Publishes Phase 2 Trial Data on Second-Line Treatment for KRAS-Mutant mCRC in *Journal of Clinical Oncology*

Advanced Genomics APAC and Compass Bioinformatics Forge Strategic Alliance to Enhance Rare Disease and Cancer Diagnostics in APAC Region

Telo Genomics Expands Mayo Clinic Collaboration to Advance Multiple Myeloma Prognostic Testing

Daiichi Sankyo and AstraZeneca Launch Phase 3 Trials of Datopotamab Deruxtecan-Based Combinations in Advanced Non-Small Cell Lung Cancer

FDA Approves Novartis Scemblix® for Newly Diagnosed CML, Showcasing Superior Efficacy and Improved Safety Profile

IDEAYA Biosciences Secures IND Clearance for IDE275 (GSK959) to Initiate Phase 1 Trial in MSI-High Solid Tumors

MGI Partners with OncoDNA to Enhance Precision Oncology with Compatible Genomic Solutions

Home
/
update
/
details

Aiforia and Paige form strategic partnership to advance AI integration in pathology laboratories

NextEdge Admin

04 Nov 2024

1 min 54 sec

Aiforia, a trusted provider of deep learning AI solutions for pathology, has announced a non-exclusive partnership with Paige, a leader in next-generation AI technology. This partnership aims to integrate Paige’s Diagnostic AI applications into the AiforiaⓇ Platform, offering customers enhanced functionality and performance. By combining their expertise, the two companies will drive joint commercial efforts and provide advanced AI-powered workflows to improve laboratory efficiency, diagnostic accuracy, scientific breakthroughs, and patient outcomes.

“Paige is excited to join forces with Aiforia, strengthening our leadership in the pathology industry, advancing adoption in life sciences and diagnostics, and making our powerful AI solutions accessible to more patients,” said Peter Hamilton, GM of Diagnostics at Paige.

“This partnership represents a significant milestone in our commitment to delivering advanced AI solutions that meet the evolving needs of pathology labs. Working with Paige, a pioneer in AI for pathology diagnostics, allows us to bring a compelling joint offering to our clients,” said Jukka Tapaninen, CEO of Aiforia.

The collaboration will roll out in the coming months, focusing on seamlessly integrated solutions for clinical and preclinical laboratory workflows. It will also drive product development initiatives centered on foundation models.